恩度联合顺铂用于恶性腹腔积液灌注治疗的临床疗效分析  

Analysis of the Clinical Efficacy in Treating Malignant Peritoneal Effusion by Endostar in Combination with Cisplatin

作　　者：汪博 朱飞 宋巍[2] WANG Bo;ZHU Fei;SONG Wei(The First Affiliated Hospital of Xi’an Jiaotong University,Xi’an,710061)

机构地区：[1]西安交通大学第一附属医院,710061 [2]西安市第四医院(西安市人民医院),710061

出　　处：《实用癌症杂志》2021年第10期1726-1728,1732,共4页The Practical Journal of Cancer

摘　　要：目的探讨重组人血管内皮抑制素注射液(恩度)和顺铂联合应用于恶性腹腔积液(malignant peritoneal effusion,MPE)腹腔内灌注治疗的临床疗效和安全性。方法选取MPE患者82例作为研究对象,随机分为观察组(恩度+顺铂)和对照组(单纯顺铂),每组41例。对照组单纯给予顺铂40 mg/次/周腹腔内灌注治疗,连续4周;观察组在对照组治疗基础上再给予恩度40 mg/m2/次/周,连续4周。利用客观缓解率(ORR)和Karnofsky功能状态评分(KPS)评估临床治疗效果,并通过比较肠道反应、白细胞减少、血小板减少、肝肾功能异常、发热、疲劳等不良反应的发生率来评价临床安全性。结果观察组完全缓解14例、部分缓解17例、无效加进展10例,有效率为75.6%(31/41);对照组完全缓解11例、部分缓解13例、无效加进展17例,有效率58.5%(24/41);2组有效率差异有统计学意义(P<0.05)。观察组生活质量改善率为81.5%,对照组生活质量改善率为53.4%,差异有统计学意义(P<0.05)。观察组总体不良反应发生率为34.1%,对照组体不良反应发生率为31.7%,差异无统计学意义(P>0.05)。结论恩度联合顺铂治疗MPE的临床疗效比单纯使用顺铂更加显著,并且不增加不良反应的发生率,值得在临床进行推广。Objective To study the clinical efficacy and security in treating malignant peritoneal effusion(MPE)by endostar in combination with cisplatin through pleural infusion.Methods 82 patients who were diagnosed as MPE and treated were randomly divided into the observation group(endostar in combination with cisplatin)and the control group(cisplatin alone),with 41 patients in each group.Patients in the control group were merely treated with cisplatin(40 mg/time/week)by pleural infusion for 4 weeks,this treatment protocol was combined with endostar(40 mg/m2/time/week)by pleural infusion in the observation group.The clinical efficacy of these 2 groups was compared by measuring the objective remission rate(ORR)and Karnofsky Performance Status(KPS)score.Moreover,the clinical security was compared by measuring the concurrency of gut reaction,decrease of lymphocyte and blood platelet,dysfunction of liver and kidney,fever and fatigue.Results In the“endostar in combination with cisplatin”group,14 patients were complete remission,17 patients were partial remission,10 patients were inefficiency and progression,the effective rate was 75.6%.In the“cisplatin alone”group,11 patients were complete remission,13 patients were partial remission,17 patients were inefficiency and progression,the effective rate was 58.5%.The differences in these 2 groups were significant(P<0.05).The improvement rate of the quality of life in“endostar in combination with cisplatin”group was 81.5%,this rate in“cisplatin alone”group was 53.4%,the differences in these 2 groups were significant(P<0.05).The occurrence of adverse reaction in“endostar in combination with cisplatin”group was 34.1%,this rate in“cisplatin alone”group was 31.7%,the differences in these 2 groups were not significant(P>0.05).Conclusion The clinical efficacy in treating MPE by endostar in combination with cisplatin through pleural infusion was higher than using cisplatin only,and the occurrence of adverse reaction was not elevated,which indicated that this treatmen

关 键 词：恩度 恶性腹腔积液 临床疗效 安全性 

分 类 号：R730.6[医药卫生—肿瘤]